What is the treatment protocol for an adult patient with actinic keratosis or superficial basal cell carcinoma using Aldara cream (imiquimod)?

Aldara (Imiquimod) Cream Treatment Protocol

For Actinic Keratosis

Apply imiquimod 5% cream to the affected area on the face or scalp 3 times per week for 4 weeks, which can be repeated for another 4 weeks if needed, with application at night for approximately 8 hours before washing off in the morning. 1, 2

Application Instructions

• Apply to the entire treatment area (up to 25 cm²) prior to normal sleeping hours and leave on for approximately 8 hours 2
• Wash off in the morning 1
• Treat clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses only 2
• The treatment area can be of any dimensions (e.g., 5 cm × 5 cm, 3 cm × 8.3 cm, 2 cm × 12.5 cm) 2

Expected Efficacy

• Complete clearance rates of 44-47% at 8 weeks post-treatment 1, 3, 2
• Partial clearance (≥75% of lesions cleared) occurs in 58-60% of patients 1, 2
• Long-term data shows 75.3% of patients receiving treatment 3 times weekly over 8 weeks remained clear at 16 months 1
• After median follow-up of 16 months, only 24.7% of patients who achieved complete clearance experienced recurrence 4

Critical Patient Counseling Points

• Expect moderate to severe local skin reactions including erythema (redness), scabbing, crusting, and erosions in approximately 30% of patients 1
• About 50% of patients discontinue treatment at 6 weeks due to disappearance of the AK 1
• Subclinical AK lesions may become apparent during treatment—48% of subjects experience an increase in visible AK lesions during therapy, but this does not predict poor outcomes 2, 5
• The clinical response is largely proportional to the side effects; patients with extreme reactions may still achieve good clearance 1

---

For Superficial Basal Cell Carcinoma

Apply imiquimod 5% cream to the tumor and approximately 1 cm beyond the tumor border 5 times per week for 6 weeks, with application prior to sleeping hours for approximately 8 hours. 2

Eligibility Criteria (Critical)

• Biopsy-confirmed primary superficial basal cell carcinoma only 2
• Maximum tumor diameter of 2.0 cm 2
• Located on trunk (excluding anogenital skin), neck, or extremities (excluding hands and feet) 2
• Use only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured 2
• Safety and efficacy NOT established for nodular or morpheaform (fibrosing/sclerosing) basal cell carcinoma types 2

Application Protocol

• Apply to the target tumor and approximately 1 cm (about 1/3 inch) beyond the tumor border 2
• Apply prior to normal sleeping hours for approximately 8 hours 2
• Continue 5 times per week dosing for total of 6 weeks 2

Expected Outcomes

• Clinical and histological clearance assessed at 12 weeks post-treatment 2
• Important caveat: 6% of imiquimod-treated patients who appeared clinically clear still had evidence of tumor on histological excision 2
• This necessitates histological confirmation of clearance, not just clinical assessment 2

---

Important Safety Considerations

Contraindications and Precautions

• Do not use in immunosuppressed patients—safety and efficacy not established 2
• Use with caution in patients with pre-existing autoimmune conditions 2
• Not established for Basal Cell Nevus Syndrome or Xeroderma Pigmentosum 2
• Rare but serious adverse effect: erythema multiforme involving oral mucosa, trunk, and extremities has been reported 6

Common Pitfalls to Avoid

• Do not treat hyperkeratotic or hypertrophic actinic keratoses—these are excluded from the indication 2
• Do not apply to areas within 1.0 cm of hairline, anogenital area, or hands/feet for basal cell carcinoma 2
• Start with a small test area to establish tolerance before treating the entire area, especially with sensitive patients 1

Comparative Context

• Imiquimod demonstrates superior long-term clearance (76% at 12 months) compared to cryosurgery (1%) and 5-FU (33%) in head-to-head trials 1
• However, 5-fluorouracil 5% cream remains the most effective topical field treatment with complete clearance rates of 38-70% 3
• Imiquimod causes less intense reactions than 5-FU but is more effective than diclofenac gel 1

---

Post-Treatment Monitoring

• UV protection is mandatory for all patients to prevent new lesion development 3
• Recurrence rates can reach up to 50% within the first year, necessitating ongoing monitoring 3
• For basal cell carcinoma, histological confirmation of clearance is essential given the 6% false-negative clinical assessment rate 2